Drugs / 18F-Fluorocholine
18F-Fluorocholine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03764007 | Sep 2016 → May 2021 | primary hyperparathyroidism | Thomas Hope | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05622162 | Dec 2022 → Jun 2024 | prostate cancer | ITEL Telecomunicazioni Srl | Unknown | No outcome recorded |
| Phase 3 | NCT04895631 | Jun 2021 → Dec 2025 | primary hyperparathyroidism | Thomas Hope | Completed | No outcome recorded |
| Phase 3 | NCT02074202 | Feb 2014 → Mar 2015 | hepatocellular carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04340765 | Feb 2018 → Dec 2019 | prostate cancer | Buddhist Tzu Chi General Hospital | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07218224 | — | parathyroid gland adenoma | Thomas Hope | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Fluorocholine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05622162 ↗ |
| Known as | 18F-fluorocholine (fluoromethyl-(2-hydroxyethyl)-dimethylazanium) | “18F-fluorocholine (fluoromethyl-(2-hydroxyethyl)-dimethylazanium)” NCT07218224 ↗ |
| Modality | Diagnostic / imaging agent | “F18 labeled fluorocholine PET” NCT03764007 ↗ |
| Route | Intravenous | “FCH intravenous injection” NCT02074202 ↗ |